This study is currently recruiting participants.

Verified February 2014 by EMD Serono

Sponsor:
EMD Serono

Information provided by (Responsible Party):
EMD Serono

ClinicalTrials.gov Identifier:
NCT01772004

First received: January 14, 2013
Last updated: February 3, 2014
Last verified: February 2014

Purpose

This is a Phase 1, open-label, dose-escalation trial of MSB0010718C [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications.

Condition

Solid Tumors

Intervention

Drug: MSB0010718C

Phase

Phase 1

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Cancer Melanoma

Genetic and Rare Diseases Information Center resources: Ovarian Cancer

U.S. FDA Resources

Further study details as provided by EMD Serono:

Primary Outcome Measures:

- Dose Limiting Toxicity [ Time Frame: Up to 3 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

- Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0 [ Time Frame: Screening up to 10 weeks after last treatment ] [ Designated as safety issue: Yes ]
- Pharmacokinetic parameters: AUC (0-t), AUC (0-infinity), λz, Cmax, Tmax, T(1/2) of MSB0010718C [ Time Frame: Every 6-week up to Week 25 ] [ Designated as safety issue: No ]
- Immune-related Best Overall Response (irBOR) and Best Overall Response (BOR) according to modified Immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors (RECIST version 1.1), respectively [ Time Frame: Time from inclusion in the trial until the date of first documented progression or discontinuation from the study due to any cause, up to 1 year after last treatment ]
  [ Designated as safety issue: No ]
- Immune-related Progression-Free Survival (irPFS) time and Progression-Free Survival (PFS) Time according to modified irRC and RECIST version 1.1, respectively [ Time Frame: Time from inclusion in the trial until first observation of progressive disease or death when death occurs within 12 weeks of the last tumor assessment or first administration of trial treatment (whichever is later) up to 1 year after last treatment ]

MSB0010718C in Solid Tumors - Full Text View - ClinicalTrials.gov http://clinicaltrials.gov/ct2/show/NCT01772004?term=2013-002834-19...
MSB0010718C in Solid Tumors - Full Text View - ClinicalTrials.gov

http://clinicaltrials.gov/ct2/show/NCT01772004?term=2013-002834...

[Designated as safety issue: No]
- Overall Survival Time [Time Frame: Time from randomization to death anticipated up to 2 years after last treatment]
- Pharmacodynamic profile of MSB0010718C to include serum levels of cytokines [Time Frame: Up to Week 25]
- Number of subjects with anti-MSB0010718C antibodies [Time Frame: Every 6-week up to Week 25] [Designated as safety issue: No]
- Level of PD-L1 tumor expression [Time Frame: Every 6-week up to Week 25] [Designated as safety issue: No]
- Unconfirmed response according to RECIST 1.1 [Time Frame: Week 13] [Designated as safety issue: No]
- Duration of response according to modified iRRC and RECIST 1.1 [Time Frame: Time from inclusion in the trial until the date of first documented disease progression or discontinuation from the study due to any cause, up to 1 year after last treatment] [Designated as safety issue: No]

Estimated Enrolment: 590
Study Start Date: January 2013
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)

### Eligibility

- **Ages Eligible for Study:** 18 Years and older
- **Genders Eligible for Study:** Both
- **Accepts Healthy Volunteers:** No

#### Inclusion Criteria for dose escalation and expansion phase:

- Signed written informed consent
- Male or female subjects aged greater than or equal to 18 years
- Subjects must have histologically or cytologically proven metastatic or locally advanced solid tumors, for which no standard therapy exists or standard therapy has failed. Availability of tumor archival material or fresh biopsies is optional for subjects in dose escalation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months
- Disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST 1.1, except for subjects with metastatic castrate-resistant prostate cancer (mCRPC) or metastatic breast cancer (MBC) who may be enrolled with objective evidence of disease without a measurable lesion
- Adequate hematological, hepatic and renal function as defined in the protocol
- Effective contraception for both male and female subjects if the risk of conception exists
- Other protocol defined inclusion criteria could apply

#### Inclusion Criteria for expansion phase:

- Subjects must have relapsed, refractory, or progressive disease following last line of treatment. Availability of tumor archival material or fresh biopsies is mandatory for eligibility in the expansion cohorts. For subjects in the MBC cohort, the biopsy or surgical specimen must have been collected within 90 days prior to the first investigational medicinal product (IMP) administration. Specifically, the following will be required:
  - For NSCLC, patients must have stage IV NSCLC or stage IIB melanoma or stage III/IV metastatic breast cancer (MBC) and have tumor that is refractory to or progressive after standard care therapy. Subjects must have received no more than 3 prior lines of cytotoxic therapy for metastatic disease. Subjects must have received a taxane and an anthracycline, unless contra-indicated
  - Metastatic colorectal cancer (mCRC), Metastatic castrate-resistant prostate cancer (mCRPC), melanoma and ovarian cancer as defined in the

### Arms

<table>
<thead>
<tr>
<th>Arms</th>
<th>Assigned Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experimental: MSB0010718C</td>
<td>Drug: MSB0010718C (anti PD-L1) will be administered in study location using a protocol-defined dose escalation scheme until confirmed progression, unacceptable toxicity, or if any criterion for withdrawal from the trial or investigational medicinal product occurs. After determination of the dose and regimen for Expansion Phase, MSB0010718C will be administered to subjects divided into 3 primary cohorts of non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (GEJ) cancer and metastatic breast cancer (MBC); and 4 secondary cohorts of colorectal cancer (CRC), castrate-resistant prostate cancer (CRPC), melanoma, and ovarian cancer. Other Name: anti PD-L1</td>
</tr>
</tbody>
</table>

Exclusion Criteria for dose escalation and expansion phase:

- Concurrent treatment with a non-permitted drug
- Prior therapy with specific antibody/drug targeting T cell co-regulatory proteins (immune checkpoints)
- Concurrent anticancer treatment concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of trial treatment. Short-term administration of steroids (that is, for allergic reactions or the management of immune-related adverse events [irAE]) is allowed. Note: Subjects receiving bisphosphonate are eligible provided treatment was initiated at least 14 days before the first dose of MSB0010718C
- Previous malignant disease other than the target malignancy to be investigated in this trial within the last 5 years with the exception of basal or squamous cell carcinoma of the skin or cervical carcinoma in situ
- Rapidly progressive disease (for example, tumor lysis syndrome)
- Active or history of central nervous system metastases
- Receipt of any organ transplantation including allogeneic stem-cell transplantation
- Significant acute or chronic infections as defined in the protocol
- Active or history of any autoimmune disease (except for subjects with vitiligo) or immunodeficiencies
- Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma
- Persisting toxicity related to prior therapy greater than Grade 1 NCI-CTCAE v4.0, however sensory neuropathy less than or equal to Grade 2 is acceptable
- Pregnancy or lactation period
- Known alcohol or drug abuse
- Clinically significant (that is, active) cardiovascular disease
- All other significant diseases (for example, inflammatory bowel disease), which, in the opinion of the investigator, might impair the subject’s tolerance of trial treatment
- Any psychiatric condition that would prohibit the understanding or rendering of informed consent
- Legal incapacity or limited legal capacity
- Non-oncology vaccine therapies for prevention of infection disease (for example, seasonal flu vaccine, human papilloma virus vaccine) within 4 weeks of study drug administration. Vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine
Please contact the Merck KGaA Communication Center
Médecins, Budapest, Hungary
Contact    +49 6151 72 5200    service@merckgroup.com

Not yet recruiting

Poland
Please contact the Merck KGaA Communication Center
Warszawa, Poland
Contact    +49 6151 72 5200    service@merckgroup.com

Not yet recruiting

United Kingdom
Please contact the Merck KGaA Communication Center
London, United Kingdom
Contact    +49 6151 72 5200    service@merckgroup.com

Not yet recruiting

Sponsors and Collaborators
EMD Serono

Investigators
Study Director: Medical Responsible EMD Serono, Inc.

More Information
No publications provided

Responsible Party: EMD Serono
ClinicalTrials.gov Identifier: NCT01772004
Other Study ID Numbers: EMR 100070-001, 2013-002834-19
Study First Received: January 14, 2013
Last Updated: February 3, 2014
Health Authority: United States: Food and Drug Administration
Belgium: Federal Agency for Medicines and Health Products, FAMHP
Czech Republic: State Institute for Drug Control
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Germany: Federal Institute for Drugs and Medical Devices
Hungary: Ministry of Health, Social and Family Affairs
Poland: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by EMD Serono:
Solid Tumors
MSB0010718C
Phase 1
Pharmacokinetic
anti PD-L1
Non-small cell lung cancer (NSCLC)

Metastatic breast cancer (MBC)
Gastric and gastroesophageal junction (GEJ) cancer
Ovarian cancer
Colorectal cancer (CRC)
Castrate-resistant prostate cancer (CRPC)
Melanoma

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on March 23, 2014